John G. McHutchison

77.8k total citations · 19 hit papers
467 papers, 43.6k citations indexed

About

John G. McHutchison is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, John G. McHutchison has authored 467 papers receiving a total of 43.6k indexed citations (citations by other indexed papers that have themselves been cited), including 415 papers in Hepatology, 339 papers in Epidemiology and 64 papers in Rheumatology. Recurrent topics in John G. McHutchison's work include Hepatitis C virus research (386 papers), Liver Disease Diagnosis and Treatment (260 papers) and Hepatitis B Virus Studies (210 papers). John G. McHutchison is often cited by papers focused on Hepatitis C virus research (386 papers), Liver Disease Diagnosis and Treatment (260 papers) and Hepatitis B Virus Studies (210 papers). John G. McHutchison collaborates with scholars based in United States, France and Germany. John G. McHutchison's co-authors include Janice K. Albrecht, Zachary Goodman, Stuart C. Gordon, Michael P. Manns, Mitchell L. Shiffman, Vinod K. Rustgi, Thierry Poynard, Keyur Patel, Kenneth Koury and Andrew J. Muir and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

John G. McHutchison

455 papers receiving 42.3k citations

Hit Papers

Peginterferon alfa-2b plu... 1995 2026 2005 2015 2001 1998 2009 2009 2012 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    2001 4.8k citations John G. McHutchison, Stuart C. Gordon et al. profile →
  2. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
    1998 2.8k citations John G. McHutchison, Stuart C. Gordon et al. profile →
  3. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    2009 2.6k citations Alexander Thompson, Kevin V. Shianna et al. profile →
  4. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
    2009 1.6k citations John G. McHutchison, David B. Goldstein et al. profile →
  5. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
    2012 1.3k citations Patrick Marcellin, Edward Gane et al. profile →
  6. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
    2009 889 citations John G. McHutchison, Andrew J. Muir et al. profile →
  7. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
    2002 849 citations John G. McHutchison, Zachary Goodman et al. profile →
  8. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
    2009 803 citations John G. McHutchison, Gregory T. Everson et al. profile →
  9. Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
    2002 775 citations John G. McHutchison, Keyur Patel et al. profile →
  10. Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis C
    2003 625 citations John G. McHutchison, Janice K. Albrecht et al. Hepatology profile →
  11. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
    2014 592 citations Alessandra Mangia, G. Mani Subramanian et al. profile →
  12. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C
    2001 548 citations Zachary Goodman, John G. McHutchison et al. Journal of Hepatology profile →
  13. Telaprevir for Previously Treated Chronic HCV Infection
    2010 529 citations John G. McHutchison, Andrew J. Muir et al. profile →
  14. Ethical and Scientific Implications of the Globalization of Clinical Research
    2009 458 citations John G. McHutchison et al. profile →
  15. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
    2013 438 citations Fred Poordad, John G. McHutchison et al. profile →
  16. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
    2017 435 citations G. Mani Subramanian, John G. McHutchison et al. Hepatology profile →
  17. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif.
    1995 283 citations Andreas Cerny, John G. McHutchison et al. Journal of Clinical Investigation profile →
  18. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.
    1996 261 citations John G. McHutchison, Michael Houghton et al. Journal of Clinical Investigation profile →
  19. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
    2019 255 citations John G. McHutchison, G. Mani Subramanian et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John G. McHutchison United States 95 37.2k 33.6k 4.7k 3.7k 3.0k 467 43.6k
Jay H. Hoofnagle United States 109 30.1k 0.8× 30.6k 0.9× 3.8k 0.8× 2.6k 0.7× 2.7k 0.9× 393 43.8k
Mitchell L. Shiffman United States 75 27.9k 0.7× 27.7k 0.8× 2.8k 0.6× 2.4k 0.6× 1.2k 0.4× 275 34.4k
Adrian M. Di Bisceglie United States 89 24.7k 0.7× 24.4k 0.7× 2.2k 0.5× 2.2k 0.6× 1.6k 0.5× 385 34.5k
Stefan Zeuzem Germany 101 34.2k 0.9× 32.8k 1.0× 5.0k 1.1× 2.6k 0.7× 2.1k 0.7× 1.0k 47.0k
Zachary Goodman United States 88 31.0k 0.8× 33.3k 1.0× 3.4k 0.7× 2.4k 0.6× 1.2k 0.4× 299 42.1k
K. Rajender Reddy United States 88 28.3k 0.8× 24.9k 0.7× 3.9k 0.8× 1.8k 0.5× 1.3k 0.4× 586 37.2k
Thomas Berg Germany 73 20.3k 0.5× 20.4k 0.6× 3.2k 0.7× 1.3k 0.3× 2.1k 0.7× 726 28.1k
Patrick Marcellin France 99 34.2k 0.9× 34.3k 1.0× 4.1k 0.9× 2.0k 0.5× 1.3k 0.4× 635 38.8k
Thierry Poynard France 93 33.9k 0.9× 36.1k 1.1× 2.8k 0.6× 1.8k 0.5× 1.1k 0.4× 427 43.7k
Jean–Michel Pawlotsky France 82 19.7k 0.5× 17.6k 0.5× 3.5k 0.7× 1.9k 0.5× 1.5k 0.5× 467 24.6k

Countries citing papers authored by John G. McHutchison

Since Specialization
Citations

This map shows the geographic impact of John G. McHutchison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John G. McHutchison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John G. McHutchison more than expected).

Fields of papers citing papers by John G. McHutchison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John G. McHutchison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John G. McHutchison. The network helps show where John G. McHutchison may publish in the future.

Co-authorship network of co-authors of John G. McHutchison

This figure shows the co-authorship network connecting the top 25 collaborators of John G. McHutchison. A scholar is included among the top collaborators of John G. McHutchison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John G. McHutchison. John G. McHutchison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gane, Edward, Éric Sicard, Stuart C. Gordon, et al.. (2013). Safety and Pharmacodynamics of Oral TLR-7 agonist GS-9620 in patients with Chronic Hepatitis B. Hepatology. 58. 4 indexed citations
2.
Duarte‐Rojo, Andrés, Amber Thompson, Julie K. Heimbach, et al.. (2013). 505 DONOR IL28B TT-POLYMORPHISM IS ASSOCIATED WITH INCREASED INCIDENCE OF HEPATIC STEATOSIS IN LIVER TRANSPLANT PATIENTS WITH CHRONIC HEPATITIS C. Journal of Hepatology. 58. S207–S208. 1 indexed citations
3.
Naggie, Susanna, Anu Osinusi, Antonios Katsounas, et al.. (2012). Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B -unfavorable genotype patients: Impaired viral kinetics and therapeutic response. Hepatology. 56(2). 444–454. 55 indexed citations
4.
Thompson, Alexander & John G. McHutchison. (2012). Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?. Hepatology. 56(1). 373–381. 24 indexed citations
5.
Cai, Ling, et al.. (2012). Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1. The American Journal of Gastroenterology. 107(11). 1675–1683. 13 indexed citations
6.
Mangia, Alessandra, Alexander Thompson, Rosanna Santoro, et al.. (2011). Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology. 54(3). 772–780. 50 indexed citations
7.
Thompson, Alexander, Paul J. Clark, David M. Vock, et al.. (2011). PREDICTING PEGINTERFERON-alpha AND RIBAVIRIN TREATMENT RESPONSE IN GENOTYPE 1 HCV PATIENTS - SIMPLE NOMOGRAMS TO SUPPORT CLINICIANS. Hepatology. 54. 95–8. 1 indexed citations
8.
Thompson, Alex J., Rosanna Santoro, Valeria Piazzolla, et al.. (2010). Itpa Genetic Variants Are Protective Against Anemia During Antiviral Therapy for G2/3 Hcv, But Do Not Decrease the Need for Rbv Dose Reduction or Increase Svr. Hepatology. 52(4). 1 indexed citations
9.
Tillmann, Hans L., Amber Thompson, Keyur Patel, et al.. (2010). 125 IL28B POLYMORPHISM IS ASSOCIATED WITH JAUNDICE DURING ACUTE HCV INFECTION AND IS A STRONG PREDICTOR FOR SPONTANEOUS CLEARANCE IN THE PROSPECTIVE GERMAN ANTI-D COHORT. Journal of Hepatology. 52. S56–S56. 4 indexed citations
10.
Rodríguez‐Torres, M., E. Läwitz, Barbara R. Conway, et al.. (2010). 31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS. Journal of Hepatology. 52. S14–S14. 26 indexed citations
11.
Neumann, Avidan U., et al.. (2008). 818 VIRAL KINETICS AND PHARMACODYNAMICS OF ALBINTERFERON ALFA-2B IN INTERFERON TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1, CHRONIC HEPATITIS C. Journal of Hepatology. 48. S306–S306. 1 indexed citations
12.
McHutchison, John G., Gregory T. Everson, S. Gordon, et al.. (2007). [786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C. Journal of Hepatology. 46. S296–S296. 19 indexed citations
13.
Ghalib, R., E. Läwitz, B. Freilich, et al.. (2007). [649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA. Journal of Hepatology. 46. S245–S246. 7 indexed citations
14.
Bain, Vincent G., K. Kaita, Eric M. Yoshida, et al.. (2007). [9] COMPARABLE ANTIVIRAL RESPONSE RATES WITH ALBUMIN INTERFERON ALFA-2B DOSED AT Q2W OR Q4W INTERVALS IN NAIVE SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C. Journal of Hepatology. 46. S7–S7. 3 indexed citations
15.
Никитин, И. Г., A. A. Yakovlev, Pavel Bogomolov, et al.. (2007). [11] PHASE 2 STUDY OF OMEGA INTERFERON ALONE OR IN COMBINATION WITH RIBAVIRIN IN SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION. Journal of Hepatology. 46. S8–S8. 16 indexed citations
16.
Lim, Rebecca, Belinda Knight, Keyur Patel, et al.. (2006). Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. Hepatology. 43(5). 1074–1083. 41 indexed citations
17.
Monto, Alexander, Keyur Patel, Alan Bostrom, et al.. (2004). Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology. 39(3). 826–834. 126 indexed citations
18.
Pianko, Stephen, John G. McHutchison, Stuart C. Gordon, et al.. (2002). Hepatic Iron Concentration Does Not Influence Response to Therapy with Interferon Plus Ribavirin in Chronic HCV Infection. Journal of Interferon & Cytokine Research. 22(4). 483–489. 21 indexed citations
19.
Marshall, D., Ken Simpson, Michèle Martinot, et al.. (2000). Economic analysis of early serum hepatitis C virus RNA testing in patients with chronic hepatitis C on interferon therapy.. 3(1). 47–62. 1 indexed citations
20.
Cerny, Andreas, John G. McHutchison, C Pasquinelli, et al.. (1995). Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif.. Journal of Clinical Investigation. 95(2). 521–530. 283 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jay H. Hoofnagle Breakdown of academic impact, for papers by Mitchell L. Shiffman Breakdown of academic impact, for papers by Adrian M. Di Bisceglie Breakdown of academic impact, for papers by Stefan Zeuzem Breakdown of academic impact, for papers by Zachary Goodman Breakdown of academic impact, for papers by K. Rajender Reddy Breakdown of academic impact, for papers by Thomas Berg Breakdown of academic impact, for papers by Patrick Marcellin Breakdown of academic impact, for papers by Thierry Poynard Breakdown of academic impact, for papers by Jean–Michel Pawlotsky
Rankless by CCL
2026